Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer

Ma,Liang; Sato,Fuminori; Sato,Ryuta; Matsubara,Takanori; Hirai,Kenichi; Yamasaki,Mutsushi; Shin,Toshitaka; Shimada,Tatsuo; Nomura,Takeo; Mori,Kenichi; Sumino,Yasuhiro; Mimata,Hiromitsu

doi:10.3892/or.2014.3132

Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer

Authors:
- Liang Ma
- Fuminori Sato
- Ryuta Sato
- Takanori Matsubara
- Kenichi Hirai
- Mutsushi Yamasaki
- Toshitaka Shin
- Tatsuo Shimada
- Takeo Nomura
- Kenichi Mori
- Yasuhiro Sumino
- Hiromitsu Mimata
View Affiliations

Affiliations: Department of Urology, Oita University, Yufu, Oita 879-5593, Japan, Division of Urology, Nakamura Hospital, Beppu, Oita 874‑0937, Japan, Faculty of Medicine, Oita University, Yufu, Oita 879-5593, Japan, Division of Urology, Tsurumi Hospital, Beppu, Oita 874-8585, Japan
Published online on: April 9, 2014 https://doi.org/10.3892/or.2014.3132
Pages: 2482-2492
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heat shock proteins (HSPs), which are molecular chaperones that stabilize numerous vital proteins, may be attractive targets for cancer therapy. The aim of the present study was to investigate the possible anticancer effect of single or dual targeting of HSP90 and HSP70 and the combination treatment with HSP inhibitors and chemotherapeutic agents in bladder cancer cells. The expression of HSP90 and the anticancer effect of the HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) coupled with cisplatin, docetaxel, or gemcitabine were examined using immunohistochemistry, quantitative real-time PCR, cell growth, flow cytometry, immunoblots and caspase-3/7 assays. The expression of HSP70 under HSP90 inhibition and the additive effect of HSP70 inhibitor pifithrin-μ (PFT-μ) were examined by the same assays and transmission electron microscopy. HSP90 was highly expressed in bladder cancer tissues and cell lines. 17-AAG enhanced the antiproliferative and apoptotic effects of each chemotherapeutic agent. 17-AAG also suppressed Akt activity but induced the upregulation of HSP70. PFT-μ enhanced the effect of 17-AAG or chemotherapeutic agents; the triple combination of 17-AAG, PFT-μ and a chemotherapeutic agent showed the most significant anticancer effect on the T24 cell line. The combination of 17-AAG and PFT-μ markedly suppressed Akt and Bad activities. With HSP90 suppression, HSP70 overexpression possibly contributes to the avoidance of cell death and HSP70 may be a key molecule for overcoming resistance to the HSP90 inhibitor. The dual targeting of these two chaperones and the combination with conventional anticancer drugs could be a promising therapeutic option for patients with advanced bladder cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Mitra AP, Datar RH and Cote RJ: Molecular staging of bladder cancer. BJU Int. 96:7–12. 2005. View Article : Google Scholar
4	Bambury RM and Rosenberg JE: Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches. Front Pharmacol. 4:32013. View Article : Google Scholar : PubMed/NCBI
5	Luo T, Yu J, Nguyen J, et al: Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci USA. 109:10175–10180. 2012. View Article : Google Scholar : PubMed/NCBI
6	Drayton RM and Catto JW: Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 12:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
7	Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 352:2302–2313. 2005. View Article : Google Scholar : PubMed/NCBI
8	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
9	Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
10	McKiernan JM, Masson P, Murphy AM, et al: Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 24:3075–3080. 2006. View Article : Google Scholar : PubMed/NCBI
11	de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J and Verweij J: Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 78:1342–1345. 1998.PubMed/NCBI
12	McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI and Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 15:1853–1857. 1997.PubMed/NCBI
13	Toschi L, Finocchiaro G, Bartolini S, Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy. Future Oncol. 1:7–17. 2005. View Article : Google Scholar
14	Bellmunt J, Albiol S, de Olano AR, Pujadas J and Maroto P; Spanish Oncology Genitourinary Group (SOGUG). Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol. 17(Suppl 5): v113–v117. 2006. View Article : Google Scholar : PubMed/NCBI
15	Cognetti F, Ruggeri EM, Felici A, et al: Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 23:695–700. 2012. View Article : Google Scholar
16	Kim JJ: Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep. 13:147–152. 2012. View Article : Google Scholar : PubMed/NCBI
17	Neri B, Vannini L, Giordano C, et al: Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. Anticancer Drugs. 18:1207–1211. 2007. View Article : Google Scholar : PubMed/NCBI
18	Boukovinas I, Androulakis N, Vamvakas L, et al: Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Ann Oncol. 17:1687–1692. 2006. View Article : Google Scholar
19	Maloney A and Workman P: HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2:3–24. 2002. View Article : Google Scholar : PubMed/NCBI
20	Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
21	Schulte TW and Neckers LM: The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 42:273–279. 1998. View Article : Google Scholar
22	Karkoulis PK, Stravopodis DJ, Margaritis LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer. 10:4812010. View Article : Google Scholar
23	Barluenga S, Fontaine JG, Wang C, et al: Inhibition of HSP90 with pochoximes: SAR and structure-based insights. Chembiochem. 10:2753–2759. 2009. View Article : Google Scholar : PubMed/NCBI
24	Barluenga S, Wang C, Fontaine JG, et al: Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angew Chem Int Ed Engl. 47:4432–4435. 2008. View Article : Google Scholar : PubMed/NCBI
25	Solit DB, Osman I, Polsky D, et al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res. 14:8302–8307. 2008. View Article : Google Scholar : PubMed/NCBI
26	Weng SH, Tseng SC, Huang YC, Chen HJ and Lin YW: Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells. Biochem Pharmacol. 84:126–136. 2012. View Article : Google Scholar : PubMed/NCBI
27	Vasilevskaya IA, Rakitina TV and O’Dwyer PJ: Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol. 65:235–243. 2004. View Article : Google Scholar
28	Solit DB, Basso AD, Olshen AB, Scher HI and Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 63:2139–2144. 2003.PubMed/NCBI
29	Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO and Karnitz LM: Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem. 278:52572–52577. 2003. View Article : Google Scholar : PubMed/NCBI
30	Ghoshal S, Rao I, Earp JC, Jusko WJ and Wetzler M: Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol. 66:681–689. 2010. View Article : Google Scholar : PubMed/NCBI
31	Wang RE: Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr Med Chem. 18:4250–4264. 2011. View Article : Google Scholar : PubMed/NCBI
32	Leu JI, Pimkina J, Frank A, Murphy ME and George DL: A small molecule inhibitor of inducible heat shock protein 70. Mol Cell. 36:15–27. 2009. View Article : Google Scholar : PubMed/NCBI
33	Newman B, Liu Y, Lee HF, Sun D and Wang Y: HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res. 72:4551–4561. 2012. View Article : Google Scholar : PubMed/NCBI
34	Zhang H and Burrows F: Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med. 82:488–499. 2004. View Article : Google Scholar : PubMed/NCBI
35	Yoshida S, Koga F, Tatokoro M, et al: Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 10:4291–4299. 2011. View Article : Google Scholar : PubMed/NCBI
36	Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L and Kihara K: Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 131:987–996. 2012. View Article : Google Scholar : PubMed/NCBI
37	Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20:407–416. 2000.PubMed/NCBI
38	Li X, Luo R, Jiang R, Meng X, Wu X, Zhang S and Hua W: The role of the Hsp90/Akt pathway in myocardial calpain-induced caspase-3 activation and apoptosis during sepsis. BMC Cardiovasc Disord. 13:82013. View Article : Google Scholar : PubMed/NCBI
39	Evans CG, Chang L and Gestwicki JE: Heat shock protein 70 (Hsp70) as an emerging drug target. J Med Chem. 53:4585–4602. 2010. View Article : Google Scholar : PubMed/NCBI
40	Pocaly M, Lagarde V, Etienne G, et al: Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia. 21:93–101. 2007. View Article : Google Scholar : PubMed/NCBI
41	Gabai VL, Budagova KR and Sherman MY: Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene. 24:3328–3338. 2005. View Article : Google Scholar
42	Guo F, Rocha K, Bali P, et al: Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 65:10536–10544. 2005. View Article : Google Scholar : PubMed/NCBI
43	Håvik B and Bramham CR: Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines. Oncol Rep. 17:1501–1510. 2007.
44	Gao T and Newton AC: The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. J Biol Chem. 277:31585–31592. 2002. View Article : Google Scholar : PubMed/NCBI
45	Liu H, Zhang T, Chen R, McConkey DJ, Ward JF and Curley SA: Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. 176:147–153. 2012. View Article : Google Scholar : PubMed/NCBI
46	Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 23:2934–2949. 2004. View Article : Google Scholar : PubMed/NCBI